DP
EW icon

Dearborn Partners’s Edwards Lifesciences EW Stock Holding History

Dearborn Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,737
Closed -$279K – 244
2022
Q4 		$279K Buy
+3,737
New +$288K 0.01% 200
2022
Q2 		– Sell
-1,821
Closed -$214K – 261
2022
Q1 		$214K Hold
1,821
– – 0.01% 263
2021
Q4 		$236K Hold
1,821
– – 0.01% 248
2021
Q3 		$206K Buy
+1,821
New +$208K 0.01% 244

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Dearborn Partners's EW Position: Q1 2023 in Review

Dearborn Partners sold out of Edwards Lifesciences (EW) in Q1 2023, closing a stake of 3,737 shares — an estimated $279K sold.

Dearborn Partners first reported a position in EW in Q3 2021 and held it in 4 quarters. The position peaked at $279K in Q4 2022. 1,245 funds tracked by Wall St. Rank hold EW as of Q1 2023.

  • Dearborn Partners reported no remaining Edwards Lifesciences position as of Q1 2023 after selling out during the quarter.
  • Dearborn Partners sold 3,737 Edwards Lifesciences shares in Q1 2023, an estimated $279K.
  • Dearborn Partners first reported a position in Edwards Lifesciences in Q3 2021 and held it in 4 quarters.
  • Dearborn Partners's Edwards Lifesciences position peaked at $279K in Q4 2022.
  • 1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2023.

Based on Dearborn Partners's 13F filing for Q1 2023, filed 4 May 2023.